Agenus reports inducement grants under nasdaq listing rule 5635(c)(4)

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced that the compensation committee of agenus' board of directors granted, as of september 1, 2023 (“grant date”), inducement awards to robin taylor, ph.d. in connection with his appointment as chief commercial officer. the compensation committee approved the awards pursuant to agenus' 2015 inducement equity plan and in accordance with.
AGEN Ratings Summary
AGEN Quant Ranking